COMMUNIQUÉS West-GlobeNewswire

Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
16/07/2026
VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, [...]
Diagonal Therapeutics Announces First Patient Dosed in Phase 1/2 DIAMOND Clinical Trial of DIAG723 for Hereditary Hemorrhagic Telangiectasia (HHT)
16/07/2026
First-in-class clustering agonist antibody DIAG723 is designed to restore ALK1 signaling, the genetically disrupted pathway that causes abnormal vascular development, bleeding, and arteriovenous malformations (AVMs) in [...]
argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
16/07/2026
July 16, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it [...]
Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development
16/07/2026
Boehringer Ingelheim announces the start of a Phase II clinical trial evaluating the efficacy and safety of its novel triple receptor agonist, BI 3034701, in people living with obesity and overweight. 1 BI 3034701 is a [...]
Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30
16/07/2026
Leiden, the Netherlands, July 16, 2026: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the second quarter and [...]
Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals
16/07/2026
The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare Diseases Completion of the transaction gives Angelini Pharma ownership of Catalyst’s [...]
Curaechoice and Symbol Health Solutions Partner to Transform Employer Healthcare with Integrated Onsite Care and Nationwide No-Cost Access
16/07/2026
Strategic partnership combines trusted onsite care with nationwide no-cost healthcare access, making employee healthcare simpler, more connected, and more affordable. Birmingham, Alabama, July 15, 2026 (GLOBE NEWSWIRE [...]
Cytek® Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement
15/07/2026
FREMONT, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced the opening of a new innovation center in Bellevue, Washington, marking the [...]
ARCPOINT ANTICIPATES DELAY IN FILING ANNUAL FINANCIAL STATEMENTS
16/07/2026
GREENVILLE, South Carolina, July 15, 2026 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the " Company " or “ ARCpoint ”) announces that it will likely miss its filing deadline of July 29, 2026 (the “ Annual Filing [...]
Landmark ECOG-ACRIN ENDURANCE Study Co-Authored by International Myeloma Foundation Leaders Provides Evidence for Optimal Duration of Maintenance Therapy
15/07/2026
STUDIO CITY, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Study results from the randomized, prospective phase III ENDURANCE (E1A11) trial, designed and conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), were [...]
Neutrolis Announces New England Journal of Medicine Publication Demonstrating First Clinical Evidence for NET-Degrading Therapy in Severe, Treatment-Refractory Systemic Lupus Erythematosus (SLE) Caused by DNASE1L3 Deficiency
15/07/2026
Treatment with investigational DNASE1L3 analog NTR-441, which degrades neutrophil extracellular traps (NETs), resulted in rapid clinical improvement in a patient with treatment-refractory SLE Results provide first human [...]
Rakovina Therapeutics Announces $1.5 Million Private Placement
15/07/2026
VANCOUVER, British Columbia, July 15, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV)( FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)- [...]
Medicare Covers Online Therapy in New York: MMHC's Medicare-Enrolled Therapists Now Accepting New Patients Statewide at $0 to $27 Per Session
15/07/2026
Every therapist at Manhattan Mental Health Counseling is enrolled in Medicare and bills Medicare directly; no referral required, no annual session limits, exact cost confirmed before session one, and first sessions [...]
First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer
15/07/2026
First patients dosed in OPTIMAL-e 1 Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent’s Hospital Sydney. OPTIMAL-e will evaluate TLX597-Tx in earlier prostate cancer [...]
Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026
15/07/2026
RADNOR, Pa., July 15, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2026 [...]
RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer
15/07/2026
ALISO VIEJO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced a planned leadership transition effective July 20, 2026, with Aziz Mottiwala appointed President and Chief Executive [...]
PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026
15/07/2026
MENLO PARK, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2026 financial results on Wednesday, August 5, [...]
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
15/07/2026
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/ [...]
Celldex Announces Planned Transition of Chief Financial Officer
15/07/2026
HAMPTON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that Sam Martin, Senior Vice President and Chief Financial Officer, has informed the Company of his plans to retire in 2027. Mr. [...]

Pages